Bristol Myers Squibb is acquiring an Nvidia DGX SuperPOD built on its own Nvidia Vera Rubin architecture to enhance artificial intelligence capabilities within its drug discovery and development operations. The deal is set to be completed in the near future, with details of the purchase remaining undisclosed by both parties.
The acquisition aims to increase AI-driven analysis in the company's research efforts, particularly when it comes to developing new treatments for various diseases. Nvidia introduced its Vera Rubin architecture earlier this year, which has since gained attention from other tech firms and life sciences companies alike.
Bristol Myers Squibb's move is significant as it will be one of the first pharmaceutical groups to acquire a DGX SuperPOD based on Nvidia's custom-built architecture. The company believes that the integration of artificial intelligence with its existing AI capabilities will help accelerate the discovery of new treatments and improve the overall efficiency of its research process.